Recruiting Phase 2 NCT07040566

A Trial of Varenicline for E-cigarette Cessation

Trial Parameters

Condition E-cigarette Use

Sponsor Yale University

Study Type INTERVENTIONAL

Phase Phase 2

Enrollment 326

Sex ALL

Min Age 18 Years

Max Age N/A

Start Date 2025-10-14

Completion 2030-07-30

All Conditions

E-cigarette Use Vaping Nicotine Dependence

Interventions

Varenicline 1mg BIDPlacebo

Brief Summary

This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.

Eligibility Criteria

Inclusion Criteria: * report daily use of an e-cigarette containing nicotine * live in Connecticut or South Carolina Exclusion Criteria: * regular use of other tobacco products besides e-cigarettes * medical contraindications for varenicline use * current treatment for tobacco cessation * lack proficiency in English

Related Trials

NCT06066996

Evaluation of the Electronic Cigarette Withdrawal Syndrome

View Trial →

NCT07040566

A Trial of Varenicline for E-cigarette Cessation

View Trial →

VIEW ON CLINICALTRIALS.GOV ↗ MORE E-CIGARETTE USE TRIALS